When timely angioplasty is unavailable to older ST-segment elevation myocardial infarction (STEMI) patients, a modified pharmaco-invasive reperfusion strategy could be reasonable, according to the ...

The bolus thrombolytic, tenecteplase, was non-inferior to alteplase, which is given by a bolus followed by an infusion, for functional outcomes in acute ischemic stroke patients treated within 4½ ...

Tenecteplase for acute ischemic stroke provided similar safety and effectiveness outcomes as alteplase, a new study showed, suggesting the drug is a viable alternative treatment. This comparative ...

Please provide your email address to receive an email when new articles are posted on . The study included 72 individuals with ischemic stroke given alteplase and tenecteplase. No significant time ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase seems to ...

Please provide your email address to receive an email when new articles are posted on . The study examined 458 adults given IV tenecteplase or placebo 4.5 to 24 hours after stroke. At 90 days after ...

NEW ORLEANS -- IV tenecteplase (TNKase) could be beneficial as far out as 24 hours after stroke onset in people not getting mechanical thrombectomy, the OPTION trial showed. In people with acute ...

The US Food and Drug Administration has approved the thrombolytic tenecteplase for the treatment of patients with acute ischemic stroke, manufacturer Genentech announced today. The approval is based ...

MONDAY, March 24, 2025 (HealthDay News) -- For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes, according to ...